Lilly enlists a long-incubating RNA upstart in new $1.25B partnership
For nearly a decade after Imperial College London professor Nagy Habib launched MiNA Therapeutics around a new kind of RNA in 2008, the company made virtually no announcement: no venture capital raised, no collaborations signed. Now, it’s like a fire hose.
On Tuesday, MiNA announced a research collaboration with Eli Lilly worth up to $1.25 billion: $25 million upfront and $245 million in milestones for each of five potential targets. The collaborators didn’t divulge what those targets would be, but said they would come in Lilly’s “key therapeutic areas,” such as metabolic diseases and diseases of the central nervous system.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.